First, the patient’s liver and kidney function and creatine kinase should be checked as a baseline control before starting medication. Lipid monitoring: test once at 4 to 6 weeks after starting medication treatment; check every 2 to 3 months thereafter; and if reduced to and maintained at the desired level, check every once thereafter. If the target lipid level is still not reached after 3-6 months of treatment, adjust the dose or drug type, or combine drug therapy, and then recheck after 4-8 weeks. After reaching the target value extended to every six months to one year review. Liver function monitoring: Most of the liver damage caused by statins occurs 1 to 3 months after drug administration and is related to the drug dose. Therefore, liver function should be checked after the first 1 to 2 weeks of treatment, and if it is normal, it should be checked again after 2 to 3 months, and if it is still normal, it can be checked every 6 months to a year thereafter. Of course, when the patient increases the dosage of statins, the liver function should be rechecked in time. Myosin monitoring: Statin-induced myopathy is relatively rare, and severe rhabdomyolysis is even rarer. Creatine kinase is usually checked once 1 to 2 weeks after starting the drug. It is not usually necessary to check creatine kinase routinely and regularly. If there is unexplained muscle weakness, pain, or change in urine color during medication, creatine kinase needs to be checked promptly.